- Price
- $125.31
- Day
- -1.81%
- Mkt Cap
- $25.40B
- 52W Range
- $81.09 – $132.60
- Volume
- 3.69M
- Beta
- 0.77
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.
Read full article
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
Integrated Wealth Concepts LLC trimmed its holdings in Incyte Corporation (NASDAQ: INCY) by 26.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,069 shares of the biopharmaceutical company's stock after selling 5,987 shares during the quarter. Integrated Wealth Concepts
Read full article
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read full article
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Read full article
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Read full article
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Read full article
Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.
Read full article
Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.
Read full article